PublishedAugust 18, 2015

Inter Partes Review and Pharma

Here’s a video I’ve done to explain why the pharmaceutical companies’ campaign against inter partes review is disingenuous at best:

You can read more about IPRs here.

Note: There was a comment on Twitter pointing out that I don’t discuss Kyle Bass and his hedge fund’s attacks against some pharmaceutical patents using inter partes review. There are two main reasons: 1) I’ve written about Kyle Bass before, and 2) none of his petitions have gone anywhere yet and there’s no reason to think they’ll do any better than previous petitions against pharmaceutical patents.

Matt Levy

Previously, Matt was patent counsel at the Computer & Communications Industry Association

More Posts

Congress Can Find Common Ground on Transparency

Postmortems from the November 8th elections are in full swing with pundits and operatives making bold claims about what the results mean for Democrats, Republicans, and the country. The dust still has...

Federal Circuit Temporarily Pauses Judge Connolly’s Disclosure Orders In Delaware

In its order on a mandamus request filed by MAVEXAR-linked entity Nimitz Technologies LLC, the Federal Circuit has temporarily paused Judge Connolly's order that entities in his court disclose details...

With frivolous NPE patent suits clogging courts, counsel’s diligence and ethics suffer

U.S. patent litigation is big business. Billion-dollar judgments, readily available litigation financing, and favorable venues and lax filing standards mean between three and four thousand suits are f...

Subscribe to Patent Progress

No spam. Unsubscribe anytime.